Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback

Hypertension Clinical Trial

— DEPSCREEN-INFO  

Official title:

Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback: Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01879111
• Other study ID #: 01-GX-1004
• Secondary ID: DRKS00003277
• Status: Completed
• Phase: N/A
• Start date: October 2011
• Est. completion date: May 2014

Study information

• Verified date: November 2020
• Source: Universitätsklinikum Hamburg-Eppendorf
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Out-patients with coronary heart disease or hypertension will fill out a depression screening questionnaire while waiting in a cardiac clinic. Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment. Patients in the control group receive no direct screening-feedback but their cardiologist will be informed about the screening result. All patients with a positive screening-result will be contacted after one month and six months and asked for symptoms of depression, and their use of health care. The aim of this study is to evaluate the efficiency of this minimal intervention on the course of depressive symptom in patients with known coronary heart disease or hypertension.

Description:

The aim of this study is to evaluate the efficiency of a minimal intervention on the course of depressive symptoms in patients with known coronary heart disease (CHD) or hypertension. By means of a depression screening and individual patient-targeted feedback the level of depression should decrease, the percentage of treated depressed patients should increase and health economic costs should be lowered. The main hypothesis is that screening plus targeted feedback results in a greater reduction of depression than screening only.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4151
• Est. completion date: May 2014
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Gender: Both, male and female

• Minimum Age: 18 Years

• Maximum Age: no maximum age

• Attendance in a cardiac clinic;

• Clinical diagnosis of coronary heart disease or hypertension;

• Age = 18 years;

• Sufficient language skills;

• Informed consent

Exclusion Criteria:

• Life threatening health status;

• Severe somatic or/and psychological disorder that needs urgent treatment;

• Acute suicidal tendency;

• Severe cognitive or/and visual difficulties;

• Not being able to fill out questionnaires

Related Conditions & MeSH terms

• Chronic Ischaemic Heart Disease
• Coronary Artery Disease
• Depressive Episode
• Heart Diseases
• Hypertension
• Myocardial Ischemia

Intervention

Other:
• patient-targeted feedback
Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.

Locations

Country	Name	City	State
Germany	Cardiologicum Hamburg	Hamburg
Germany	University Medical Center Universitaeres Herzzentrum Hamburg-Eppendorf	Hamburg

Sponsors (2)

Lead Sponsor	Collaborator
Universitätsklinikum Hamburg-Eppendorf	German Federal Ministry of Education and Research

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Level of depression one month after screening (Patient Health Questionnaire-9)		One month after depression screening
Secondary	Level of depression six months after screening (Patient Health Questionnaire-9)		One month and six months after screening
Secondary	Proportion of patients treated for depression.		One month and six months after screening
Secondary	Direct and indirect health costs		One month and six months after screening
Secondary	Quality-adjusted years of life and quality of life (EuroQol-5D)		One month and six months after screening

External Links

•   Website of the Department of Psychosomatic Medicine (in German)